Medications like Ozempic and Wegovy are achieving unprecedented weight loss results, prompting a fundamental rethinking of obesity treatment. Demand has overwhelmed supply as millions seek access to the drugs.
Clinical trials show patients losing an average of 15-20% of body weight on semaglutide (Wegovy) and up to 22% on tirzepatide (Mounjaro). These results far exceed previous weight loss medications and approach bariatric surgery outcomes.
"We are witnessing a paradigm shift in obesity medicine," said endocrinologist Dr. Caroline Apovian. "For the first time, we have medications that address the underlying biology of obesity, not just willpower."
Insurance coverage remains inconsistent. While some employers and insurers cover the drugs, many classify them as cosmetic rather than medical necessity. Monthly costs exceed $1,000 without coverage.
Long-term effects remain unknown. Patients must continue taking the drugs indefinitely to maintain weight loss, raising questions about lifetime cost and potential side effects. Researchers are studying cardiovascular benefits beyond weight reduction.
Hotnews is a popular website featuring news from various fields, such as politics, business, sports, and entertainment. The site publishes current information and reports on topics important to society. Readers can also find expert commentary and analysis as well as videos and photos illustrating the events being discussed. Hotnews is a valuable source of information for those who want to stay up-to-date with the latest news.
